Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.
Purpose<br/> Our aim was to determine the role of end-of-induction (EOI) minimal residual disease (MRD) assessment in the identification and stratification of induction failure in patients with pediatric acute lymphoblastic leukemia (ALL) and to identify genetic abnormalities that drive...
主要な著者: | , , , , , , , , , , , , , |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
American Society of Clinical Oncology
2017
|